期刊
RHEUMATOLOGY
卷 50, 期 2, 页码 311-316出版社
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keq190
关键词
Rheumatoid factor; Anti-cyclic citrullinated peptide; Early inflammatory arthritis; Early rheumatoid arthritis; Undifferentiated inflammatory peripheral arthritis; Systematic review; Seroconversion
类别
资金
- Abbott Laboratories
- Abbott
Methods. We conducted a systematic literature review of all English publications and recent abstracts from ACR and EULAR. Patients epsilon 16 years of age with at least one swollen joint and symptoms < 2 years were included. Results. Twelve publications met the criteria: 10 studies included data on RF, while only 5 addressed anti-CCP. Sample sizes ranged from 15 to 395 and follow-up was 6-60 months. There was marked heterogeneity between studies; therefore, results could not be pooled for a meta-analysis. Baseline RF and anti-CCP positivity was also highly variable: 8-55 and 4-45%, respectively. Seroconversion rates for EIA were 1.9-5.0% at up to 30 months follow-up for RF and 1.3-8.9% at up to 60 months follow-up for anti-CCP. Conclusion. There is minimal change in RF or anti-CCP positivity up to 5 years of follow-up. Prevalence data for RF in established RA is significantly higher than the baseline values reported here. The low rates of seroconversion would suggest a lower prevalence in EIA and the reason for this difference remains unknown. It is unclear whether antibody-negative patients are more likely to remit and be lost to follow-up in established RA populations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据